<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:33:14Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2604881" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2604881</identifier><datestamp>2008-12-18</datestamp><setSpec>bmcneus</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Neurosci</journal-id>
      <journal-title>BMC Neuroscience</journal-title>
      <issn pub-type="epub">1471-2202</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2604881</article-id>
      <article-id pub-id-type="pmcid">PMC2604881</article-id>
      <article-id pub-id-type="pmc-uid">2604881</article-id>
      <article-id pub-id-type="pmid">19091000</article-id>
      <article-id pub-id-type="publisher-id">1471-2202-9-S3-S3</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2202-9-S3-S3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>NAP and D-SAL: neuroprotection against the Î² amyloid peptide (1â42)</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Gozes</surname>
            <given-names>Illana</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>igozes@post.tau.ac.il</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Divinski</surname>
            <given-names>Inna</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Piltzer</surname>
            <given-names>Inbar</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Human Molecular Genetic and Biochemistry, Sackler School of Medicine, Tel Aviv University, Einstein Street, Tel Aviv 69978, Israel</aff>
      <pub-date pub-type="collection">
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>12</month>
        <year>2008</year>
      </pub-date>
      <volume>9</volume>
      <issue>Suppl 3</issue>
      <supplement>
        <named-content content-type="supplement-title">Proceedings of the 2007 and 2008 Drug Discovery for Neurodegeneration Conference</named-content>
        <named-content content-type="supplement-editor">Howard Fillit and Antony Horton</named-content>
        <named-content content-type="supplement-sponsor">The conference and the publication of these proceedings were supported by a conference grant: U13-AG031125 from the National Institute of Aging and the National Institute for Neurological Disorders and Stroke. Additional support was provided by CoMentis, Inc; Pfizer, Inc.; Biogen Idec and Boehringer Ingelheim Pharmaceuticals, Inc.</named-content>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/content/pdf/1471-2202-9-S3-info.pdf">http://www.biomedcentral.com/content/pdf/1471-2202-9-S3-info.pdf</ext-link>
      </supplement>
      <fpage>S3</fpage>
      <lpage>S3</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2202/9/S3/S3"/>
      <permissions>
        <copyright-statement>Copyright Â© 2008 Gozes et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2008</copyright-year>
        <copyright-holder>Gozes et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Gozes
               Illana
               
               igozes@post.tau.ac.il
            </dc:author><dc:title>
            NAP and D-SAL: neuroprotection against the &#x003b2; amyloid peptide (1&#x02013;42)
         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Neuroscience 9(Suppl 3): S3-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2202(2008)9:Suppl 3&#x0003c;S3&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2202</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Introduction</title>
          <p>NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ), an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP), exhibits some structural similarity to activity-dependent neurotropic factor-9 (ADNF-9; Ser-Alal-Leu-Leu-Arg-Ser-Ile-Pro-Ala, SALLRSIPA). Both peptides are also active in the all D-amino acid conformation, termed D-NAP and D-SAL. Original results utilizing affinity chromatography coupled to mass spectrometry identified tubulin, the subunit protein of microtubules, as the major NAP-associating protein in brain. The NAP-tubulin association was found to be diminished in the presence of ADNF-9, D-NAP, and D-SAL, suggesting a common target of neuroprotection. The Î² amyloid peptide interacts with microtubules, and previous studies have demonstrated protection against Î² amyloid (25â35) toxicity by NAP and ADNF-9. NAP also inhibits Î² amyloid (25â35 and 1â40) aggregation.</p>
        </sec>
        <sec sec-type="methods">
          <title>Methods</title>
          <p>Cerebral cortical cultures derived from newborn rats were used in neuronal survival assays to test the activity of both NAP and D-SAL against the major Alzheimer's disease toxic peptide Î² amyloid (1â42).</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>NAP and D-SAL protected cerebral cortical neurons against the major Alzheimer's disease toxic peptide Î² amyloid (1â42). Maximal protection of both peptides was observed at concentrations of 10<sup>-15 </sup>to 10<sup>-10 </sup>mol/l.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>These findings, together with those of previous <italic>in vivo </italic>studies conducted in relevant Alzheimer's disease models, pave the path to drug development. Bioavailability studies indicated that NAP penetrates cells and crosses the blood-brain barrier after nasal or systemic administration. Phase II clinical trials of NAP are currently in progress by Allon Therapeutics Inc.</p>
        </sec>
      </abstract>
      <conference>
        <conf-date>Washington DC USA 4â5 February 2008</conf-date>
        <conf-name>2007 and 2008 Drug Discovery for Neurodegeneration Conference</conf-name>
        <conf-loc>New York, USA. 5-6 February 2007</conf-loc>
      </conference>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <sec>
        <title>ADNP and ADNF</title>
        <p>NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ, an eight amino acid neuroprotective peptide) is derived from activity-dependent neuroprotective protein (ADNP) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>], a protein that differentially interacts with chromatin to regulate genes that are essential for brain formation and embryogenesis [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Furthermore, recombinant ADNP is neuroprotective <italic>in vitro </italic>against severe oxidative stress and neurotoxicity associated with the Alzheimer's disease neurotoxin Î² amyloid peptide (25â35) [<xref ref-type="bibr" rid="B6">6</xref>]. ADNP synthesis and secretion is induced by the neuroprotective vasoactive intestinal peptide [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Activity-dependent neuroprotective factor (ADNF) was isolated from conditioned medium of astrocytes treated with vasoactive intestinal peptide that, in turn, was initially found to be associated with embryonic development and brain protection [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. The active core of ADNF, namely ADNF-9 (SALLRSIPA), exhibits structural and functional similarities with NAP [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p>
      </sec>
      <sec>
        <title>NAP and ADNF-9: protection against Î² amyloid toxicity</title>
        <p>A comprehensive review detailing NAP neuroprotective activity and clinical development [<xref ref-type="bibr" rid="B14">14</xref>] and a short review detailing NAP neurotropism <italic>in vitro </italic>were recently published [<xref ref-type="bibr" rid="B15">15</xref>]. Furthermore, NAP was found to enhance neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia, suggesting neurotropic activity <italic>in vivo </italic>[<xref ref-type="bibr" rid="B16">16</xref>]. NAP was initially discovered to protect against Î² amyloid (amino acids 25â35) toxicity in rat cerebral cortical neurons seeded on a bed of astrocytes, and these studies were extended to show that NAP protected against Î² amyloid (25â35) in neuronal enriched cultures [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. The primary structure of NAP includes two prolines that confer Î² sheet breaking characteristics, and NAP was shown to decrease the aggregation of the Î² amyloid peptide (25â35 and 1â40) [<xref ref-type="bibr" rid="B18">18</xref>].</p>
        <p>The function and properties of ADNF-9 were recently reviewed [<xref ref-type="bibr" rid="B11">11</xref>]. Regarding Alzheimer's disease, ADNF-9 protects against the toxicity of Î² amyloid peptide (25â35) [<xref ref-type="bibr" rid="B9">9</xref>] and (1â42) [<xref ref-type="bibr" rid="B19">19</xref>]. In addition, primary hippocampal neurons from presenilin 1 mutant knock-in mice, exhibiting increased production of amyloid Î² peptide 42â43 and increased vulnerability to excitotoxicity, were protected by pretreatment with ADNF-9 [<xref ref-type="bibr" rid="B20">20</xref>].</p>
        <p>The all D-amino acid analogs of NAP and ADNF-9 (D-NAP and D-SAL, respectively) have both been found to exhibit neuroprotective activity [<xref ref-type="bibr" rid="B21">21</xref>]. Here, we present data on the novel finding that NAP and D-SAL also protect against Î² amyloid (1â42) toxicity.</p>
      </sec>
    </sec>
    <sec sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec sec-type="materials">
        <title>Materials</title>
        <p>The octapeptides NAP and D-SAL were synthesized by Professor M Fridkin and Ms S Rubinraut at the Department of Organic Chemistry of the Weizmann Institute of Science (Rehovot, Israel) and Bachem (Torrance, CA, USA).</p>
        <p>All peptides were dissolved in distilled sterile water to a concentration of 1 mmol/l and then diluted in water in 1:10 steps down to the required concentration. The Î² amyloid peptide (1â42) was obtained from American Peptides Company (Sunnyvale, CA, USA).</p>
      </sec>
      <sec>
        <title>Cell cultures and neuronal survival</title>
        <p>Cerebral cortical cultures derived from newborn rats were used for neuron survival assays. For mixed neuroglial cultures, neurons (300,000 cells/35 mm dish) were seeded on 8-day-old astrocytes prepared as described [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Cells were allowed to grow for 1 week at 37Â°C (10% carbon dioxide) before experiments were performed. Four days after neuronal plating, cultures were given their respective treatment and assayed for neuronal survival after an additional 5-day incubation period.</p>
      </sec>
      <sec>
        <title>Neuronal cell counts</title>
        <p>The culture medium was removed and cells were washed twice with phosphate buffered saline. A volume of 1.5 ml of 3% gluteraldehyde (Fluka Biochemika, Steinheim, Germany) in 0.1 mol/l cacodylic acid (pH 7.2; Fluka Biochemika) was added for 2 hours. The cells were then washed with phosphate buffered saline and 2 ml of 0.15 mol/l cacodylic acid (pH 7.2) was added. Neuronal identity was established by morphological criteria using an Olympus CK2 light microscope (Olympus, Tokyo, Japan) with a 40Ã lens. Fifty fields were counted per dish [<xref ref-type="bibr" rid="B17">17</xref>].</p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <p>The number of surviving neurons was assessed in cerebral cortical cultures derived from newborn rats using 2.5 Î¼mol/l of Î² amyloid peptide (1â42), a toxin associated with Alzheimer's disease. NAP and D-SAL were used at the following concentrations: 10<sup>-16 </sup>mol/l, 10<sup>-15 </sup>mol/l, 10<sup>-12 </sup>mol/l, and 10<sup>-10 </sup>mol/l. The peptides protected against neurotoxicity associated with the Î² amyloid peptide (1â42; <italic>P </italic>&lt; 0.001). Maximal protection of both peptides was observed at concentrations of 10<sup>-15 </sup>mol/l to 10<sup>-10 </sup>mol/l (Figure <xref ref-type="fig" rid="F1">1</xref>). No differences were observed between NAP and D-SAL in terms of neuroprotection. Cell counts totaled more than 100% of control. This may be because the treatment prevented neuronal cell death that occurred naturally in the cultures (10% to 20%), as previously observed [<xref ref-type="bibr" rid="B1">1</xref>].</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p>The eight and nine amino acid peptides (NAP and D-SAL, respectively) provide neuroprotection against Î² amyloid (1â42). Mixed neuroglial cultures were exposed to 2.5 Î¼mol/l Î² amyloid peptide (1â42) for 5 days, resulting in about 40% cell death. The respective peptides were added together with the toxin at indicated concentrations (10<sup>-16 </sup>mol/l, 10<sup>-15 </sup>mol/l, 10<sup>-12 </sup>mol/l, and 10<sup>-10 </sup>mol/l). Experiments were repeated at least three times. Results were normalized by untreated cells. ***<italic>P </italic>&lt; 0.001, cells treated with either NAP or D-SAL versus Î² amyloid alone (without peptide treatment). D-SAL, D-amino acid analog of activity-dependent neuroprotective factor 9; NAP, Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ, an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein.</p>
        </caption>
        <graphic xlink:href="1471-2202-9-S3-S3-1"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <sec>
        <title>Interactions of NAP and D-SAL with microtubules</title>
        <p>The Î² amyloid peptide (1â42) has been shown to aggregate into oligomers along microtubules of neuronal processes, both in Tg2576 mice and human Alzheimer's disease brain [<xref ref-type="bibr" rid="B22">22</xref>]. In triple transgenic Alzheimer's disease mice expressing three mutant transgenes (amyloid precursor protein [double Swedish, K670M/N671L], presenilin 1 [M146V], and tau [P301L]) [<xref ref-type="bibr" rid="B23">23</xref>], Î² amyloid accumulation occurs before tau hyperphosphorylation. These findings have been suggested to imply, at least in part, a possible cause and effect relationship between Î² amyloid and tau pathology. A main target of NAP in neuroprotection appears to be tubulin, which is the major subunit of microtubules. Affinity chromatography studies utilizing immobilized NAP identified tubulin as the NAP associating protein [<xref ref-type="bibr" rid="B24">24</xref>]. D-SAL diminished tubulin association with the NAP affinity column, suggesting an interaction of tubulin with D-SAL as well [<xref ref-type="bibr" rid="B25">25</xref>]. Tubulin antibodies identified NAP interaction with the neuron-specific tubulin subunit Î² III, as well as with astrocyte tubulin [<xref ref-type="bibr" rid="B26">26</xref>]. Further studies showed that although vincristine (which enhances microtubule depolymerization and crystal formation) did not diminish the interaction of NAP with tubulin, paclitaxel (a microtubule stabilizing agent) did diminish this interaction [<xref ref-type="bibr" rid="B26">26</xref>]. NAP accelerated microtubule formation after nocodazole depolymerization in neurons [<xref ref-type="bibr" rid="B27">27</xref>]. Furthermore, NAP prevented microtubule disassembly caused by zinc chloride intoxication in astrocytes [<xref ref-type="bibr" rid="B24">24</xref>] and in neurons [<xref ref-type="bibr" rid="B26">26</xref>].</p>
        <p>The temporal changes in microtubule assembly that followed NAP treatment in cells paralleled changes in phosphorylation of the tubulin-associated protein, tau [<xref ref-type="bibr" rid="B28">28</xref>]. This finding suggests that NAP regulates tau phosphorylation alongside microtubule dynamics and protects astrocytes and neurons. In the triple transgenic Alzheimer's disease mouse model, NAP reduced tau hyperphosphorylation [<xref ref-type="bibr" rid="B29">29</xref>]. Because tau hyperphosphorylation has been associated with major neurodegenerative diseases, including Alzheimer's disease, NAP holds promise as a neuroprotective/neurotropic drug candidate.</p>
      </sec>
      <sec>
        <title>Bioavailability</title>
        <sec>
          <title>Cellular bioavailability</title>
          <p>Fluoresceine-labeled NAP was detected in the intracellular milieu of neurons and astrocytes. In astrocytes, labeled NAP was found even when incubated at 4Â°C and in conditions of low pH, indicating membrane permeability. Furthermore, comparison of NAP with known membrane permeating peptides has revealed that NAP possesses a membrane permeation structure [<xref ref-type="bibr" rid="B24">24</xref>]. Because both NAP and ADNF-9 are active in their all D-amino acid conformation, these peptides were suggested to be mechanistically achiral [<xref ref-type="bibr" rid="B21">21</xref>]. It is our working hypothesis that NAP interacts with intracellular tubulin to enhance microtubule polymerization and provide cellular protection. However, NAP interacts with specific tubulin subunits and does not provide protection to all cells. Indeed, NAP did not protect fibroblast-like cells, but did protect neuronal-like cells against oxidative stress [<xref ref-type="bibr" rid="B26">26</xref>]. These results are in accordance with our original studies suggesting that NAP selectively interacts with brain specific tubulin subunits that are associated with multiple tubulin functions [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B32">32</xref>].</p>
        </sec>
        <sec>
          <title>Brain bioavailability and clinical development</title>
          <p>The pharmacodynamic compartment for NAP is the brain or the central nervous system. When NAP is administered it must be able to reach this target compartment at pharmacologically active concentrations. As shown in Figure <xref ref-type="fig" rid="F1">1</xref>, NAP exhibits an <italic>in vitro </italic>potency of about 10<sup>-15 </sup>mol/l. Preclinical and phase I clinical experiments demonstrated that intranasal administration of NAP to rat, dog, or human results in measurable plasma levels [<xref ref-type="bibr" rid="B14">14</xref>]. After intranasal administration of [<sup>3</sup>H]NAP to rats, radioactivity was detected in the blood and was also measured in the various organs of the body [<xref ref-type="bibr" rid="B33">33</xref>]. Intact peptide was identified in the rat cortex 30 and 60 minutes after intranasal administration. In the permanent middle cerebral artery occlusion rat model, intravenous administration of radioactive NAP resulted in measurable levels in the cerebellum and cortex 15 minutes after injection and was maintained for at least 30 minutes in ischemic tissue [<xref ref-type="bibr" rid="B34">34</xref>]. Liquid chromatography mass spectrometry assays in rats and dogs corroborated and extended these results. Recent data from a pharmacokinetic study conducted in rats suggested a correlation between plasma and cerebrospinal fluid levels of NAP administered by intravenous injection. After intranasal administration in the rat, appeared NAP rapidly in plasma and the kinetics of appearance in cerebrospinal fluid (T<sub>max</sub>) appeared to lag plasma T<sub>max </sub>[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. It is therefore likely that access to the brain is via the circulation for both intravenous and intranasal routes.</p>
        </sec>
      </sec>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>NAP and D-SAL protect against the Alzheimer's disease neurotoxin Î² amyloid peptide (1â42), which suggests potential treatments for Alzheimer's disease pathology. This finding, together with previous findings including animal efficacy and bioavailability studies, steer these compounds toward clinical development. Allon Therapeutics Inc. [<xref ref-type="bibr" rid="B36">36</xref>] recently released top-line results of a phase IIa clinical trial showing that its drug AL-108 (the intranasal formulation of NAP) has a positive impact on memory function in patients with amnestic mild cognitive impairment, which is a precursor to Alzheimer's disease.</p>
    </sec>
    <sec>
      <title>List of abbreviations used</title>
      <p>ADNF: activity-dependent neuroprotective factor; ADNP: activity-dependent neuroprotective protein; NAP: Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (single amino acid letter code, NAPVSIPQ).</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>NAP and D-SAL are under patent protection and licensed for clinical development to Allon Therapeutics Inc. IG serves as the Chief Scientific Officer of Allon Therapeutics Inc.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>IG conceived of the study, and participated in its design and coordination. IN and IP carried out the experiments. IG drafted the manuscript. All authors participated in writing, and read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>We thank the Allon Therapeutics Inc. team for excellent suggestions. Professor Illana Gozes is the incumbent of the Lily and Avraham Gildor Chair for the Investigation of Growth Factors, is the Director of the Adams Super Center for Brain Studies and the Levie-Adesheim-Gitter fMRI Institute, and heads the Dr Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology. Supported by ISF, BSF, NICHD, NIA, ISOA, and Allon Therapeutics Inc.</p>
        <p>This article has been published as part of <italic>BMC Neuroscience </italic>Volume 9 Supplement 3, 2008: Proceedings of the 2007 and 2008 Drug Discovery for Neurodegeneration Conference. The full contents of the supplement are available online at <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2202/9?issue=S3"/>.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bassan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zamostiano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pinhasov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Perl</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bassan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Blat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gibney</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Glazner</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide</article-title>
          <source>J Neurochem</source>
          <year>1999</year>
          <volume>72</volume>
          <fpage>1283</fpage>
          <lpage>1293</lpage>
          <pub-id pub-id-type="pmid">10037502</pub-id>
          <pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0721283.x</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neuroprotective protein: from gene to drug candidate</article-title>
          <source>Pharmacol Ther</source>
          <year>2007</year>
          <volume>114</volume>
          <fpage>146</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="pmid">17363064</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.pharmthera.2007.01.004</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pinhasov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mandel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Torchinsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pittel</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Goldsweig</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Servoss</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neuroprotective protein: a novel gene essential for brain formation</article-title>
          <source>Brain Res Dev Brain Res</source>
          <year>2003</year>
          <volume>144</volume>
          <fpage>83</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">12888219</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0165-3806(03)00162-7</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rechavi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis</article-title>
          <source>Dev Biol</source>
          <year>2007</year>
          <volume>303</volume>
          <fpage>814</fpage>
          <lpage>824</lpage>
          <pub-id pub-id-type="pmid">17222401</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.ydbio.2006.11.039</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex</article-title>
          <source>J Biol Chem</source>
          <year>2007</year>
          <volume>282</volume>
          <fpage>34448</fpage>
          <lpage>34456</lpage>
          <pub-id pub-id-type="pmid">17878164</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M704756200</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steingart</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress</article-title>
          <source>Mol Cell Endocrinol</source>
          <year>2006</year>
          <volume>252</volume>
          <fpage>148</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">16704895</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.mce.2006.03.029</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Steingart</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Mandel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hauser</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes</article-title>
          <source>Neuron Glia Biol</source>
          <year>2004</year>
          <volume>1</volume>
          <fpage>193</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">16845437</pub-id>
          <pub-id pub-id-type="doi">10.1017/S1740925X05000013</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mascolo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barth</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hauser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity</article-title>
          <source>Brain Res Dev Brain Res</source>
          <year>1997</year>
          <volume>99</volume>
          <fpage>167</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">9125470</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0165-3806(96)00215-5</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>A femtomolar-acting neuroprotective peptide</article-title>
          <source>J Clin Invest</source>
          <year>1996</year>
          <volume>97</volume>
          <fpage>2299</fpage>
          <lpage>2307</lpage>
          <pub-id pub-id-type="pmid">8636410</pub-id>
          <pub-id pub-id-type="doi">10.1172/JCI118672</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?</article-title>
          <source>J Mol Neurosci</source>
          <year>1996</year>
          <volume>7</volume>
          <fpage>235</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="pmid">8968945</pub-id>
          <pub-id pub-id-type="doi">10.1007/BF02737061</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Vulih</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Spivak-Pohis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Furman</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Henderson B, Pockley AG</surname>
            </name>
          </person-group>
          <article-title>Neuroendocrine aspects of the molecular chapernoes ADNF and ADNP</article-title>
          <source>Molecular Chaperones and Cell Signalling</source>
          <year>2005</year>
          <publisher-name>Cambridge, UK: Cambridge University Press</publisher-name>
          <fpage>251</fpage>
          <lpage>262</lpage>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bassan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zamostiano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pinhasov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Perl</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Glazner</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>1999</year>
          <volume>897</volume>
          <fpage>125</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">10676441</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb07884.x</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Hauser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neale</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rubinraut</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fridkin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1998</year>
          <volume>285</volume>
          <fpage>619</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="pmid">9580606</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Morimoto</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Tiong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sutherland</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dangoor</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Holser-Cochav</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vered</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Newton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Aisen</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Matsuoka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>van Dyck</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Thal</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)</article-title>
          <source>CNS Drug Rev</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>353</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="pmid">16614735</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Spivak-Pohis</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate</article-title>
          <source>Curr Alzheimer Res</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>197</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">16842095</pub-id>
          <pub-id pub-id-type="doi">10.2174/156720506777632790</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rotstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bassan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kariv</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Speiser</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Harel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2006</year>
          <volume>319</volume>
          <fpage>332</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="pmid">16822898</pub-id>
          <pub-id pub-id-type="doi">10.1124/jpet.106.106898</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zemlyak</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Furman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>A novel peptide prevents death in enriched neuronal cultures</article-title>
          <source>Regul Pept</source>
          <year>2000</year>
          <volume>96</volume>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">11102650</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0167-0115(00)00198-1</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ashur-Fabian</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Segal-Ruder</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Skutelsky</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Steingart</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide</article-title>
          <source>Peptides</source>
          <year>2003</year>
          <volume>24</volume>
          <fpage>1413</fpage>
          <lpage>1423</lpage>
          <pub-id pub-id-type="pmid">14706557</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.peptides.2003.08.005</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hashimoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsukamoto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Frankowski</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kouyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Niikura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aiso</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bredesen</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Matsuoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nishimoto</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD</article-title>
          <source>J Neurochem</source>
          <year>2004</year>
          <volume>90</volume>
          <fpage>549</fpage>
          <lpage>558</lpage>
          <pub-id pub-id-type="pmid">15255932</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02513.x</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Sebastian</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sopher</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Glazner</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Ware</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Mattson</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>4125</fpage>
          <lpage>4130</lpage>
          <pub-id pub-id-type="pmid">10097174</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.96.7.4125</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Spong</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Hauser</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Abebe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pinhasov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Golian</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Protective peptides that are orally active and mechanistically nonchiral</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2004</year>
          <volume>309</volume>
          <fpage>1190</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="pmid">15007105</pub-id>
          <pub-id pub-id-type="doi">10.1124/jpet.103.063891</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Kearney</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Milner</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Gouras</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain</article-title>
          <source>J Neurosci</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>3592</fpage>
          <lpage>3599</lpage>
          <pub-id pub-id-type="pmid">15071107</pub-id>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5167-03.2004</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oddo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caccamo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Golde</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Kayed</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Metherate</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mattson</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Akbari</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>LaFerla</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction</article-title>
          <source>Neuron</source>
          <year>2003</year>
          <volume>39</volume>
          <fpage>409</fpage>
          <lpage>421</lpage>
          <pub-id pub-id-type="pmid">12895417</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0896-6273(03)00434-3</pub-id>
        </citation>
      </ref>
      <ref id="B24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Divinski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mittelman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>28531</fpage>
          <lpage>28538</lpage>
          <pub-id pub-id-type="pmid">15123709</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M403197200</pub-id>
        </citation>
      </ref>
      <ref id="B25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holtser-Cochav</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Divinski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL</article-title>
          <source>J Mol Neurosci</source>
          <year>2006</year>
          <volume>28</volume>
          <fpage>303</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="pmid">16691018</pub-id>
          <pub-id pub-id-type="doi">10.1385/JMN:28:3:303</pub-id>
        </citation>
      </ref>
      <ref id="B26">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Divinski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Holtser-Cochav</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vulih-Schultzman</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Steingart</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Peptide neuroprotection through specific interaction with brain tubulin</article-title>
          <source>J Neurochem</source>
          <year>2006</year>
          <volume>98</volume>
          <fpage>973</fpage>
          <lpage>984</lpage>
          <pub-id pub-id-type="pmid">16893427</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03936.x</pub-id>
        </citation>
      </ref>
      <ref id="B27">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Divinski</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell</article-title>
          <source>Curr Alzheimer Res</source>
          <year>2007</year>
          <volume>4</volume>
          <fpage>507</fpage>
          <lpage>509</lpage>
          <pub-id pub-id-type="pmid">18220512</pub-id>
          <pub-id pub-id-type="doi">10.2174/156720507783018208</pub-id>
        </citation>
      </ref>
      <ref id="B28">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Divinski</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection</article-title>
          <source>J Alzheimers Dis</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>S37</fpage>
          <lpage>S41</lpage>
          <pub-id pub-id-type="pmid">15665412</pub-id>
        </citation>
      </ref>
      <ref id="B29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsuoka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jouroukhin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hirata-Fukae</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lecanu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Planel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Arancio</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Aisen</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2008</year>
          <volume>325</volume>
          <fpage>146</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">18199809</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jalz.2006.05.2074</pub-id>
        </citation>
      </ref>
      <ref id="B30">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Littauer</surname>
              <given-names>UZ</given-names>
            </name>
          </person-group>
          <article-title>Tubulin microheterogeneity increases with rat brain maturation</article-title>
          <source>Nature</source>
          <year>1978</year>
          <volume>276</volume>
          <fpage>411</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">714168</pub-id>
          <pub-id pub-id-type="doi">10.1038/276411a0</pub-id>
        </citation>
      </ref>
      <ref id="B31">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sweadner</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Multiple tubulin forms are expressed by a single neurone</article-title>
          <source>Nature</source>
          <year>1981</year>
          <volume>294</volume>
          <fpage>477</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="pmid">7312039</pub-id>
          <pub-id pub-id-type="doi">10.1038/294477a0</pub-id>
        </citation>
      </ref>
      <ref id="B32">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Barnstable</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Monoclonal antibodies that recognize discrete forms of tubulin</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1982</year>
          <volume>79</volume>
          <fpage>2579</fpage>
          <lpage>2583</lpage>
          <pub-id pub-id-type="pmid">6178107</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.79.8.2579</pub-id>
        </citation>
      </ref>
      <ref id="B33">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pinhasov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bardea</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2000</year>
          <volume>293</volume>
          <fpage>1091</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="pmid">10869414</pub-id>
        </citation>
      </ref>
      <ref id="B34">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leker</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Teichner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grigoriadis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ovadia</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brenneman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Fridkin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death</article-title>
          <source>Stroke</source>
          <year>2002</year>
          <volume>33</volume>
          <fpage>1085</fpage>
          <lpage>1092</lpage>
          <pub-id pub-id-type="pmid">11935065</pub-id>
          <pub-id pub-id-type="doi">10.1161/01.STR.0000014207.05597.D7</pub-id>
        </citation>
      </ref>
      <ref id="B35">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morimoto</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>de Lannoy</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Gien</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tiong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gozes</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of the neuroprotective peptide, NAPVSIPQ in serial samples of plasma and CSF after intravenous or intranasal administration</article-title>
          <source>Drug Metab Rev</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>213</fpage>
          <lpage>214</lpage>
        </citation>
      </ref>
      <ref id="B36">
        <citation citation-type="other">
          <article-title>Allon Therapeutics Inc</article-title>
          <ext-link ext-link-type="uri" xlink:href="http://www.allontherapeutics.com"/>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>